← Back
NeuroTrials.ai
Neurology Clinical Trial Database

SINGLE-AF

Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk (Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants for Intermediate Stroke Risk in Patients with Atrial Fibrillation)

Year of Publication: 2026

Authors: Daehoon Kim, Young Soo Lee, Jaemin Shim, ..., for the SINGLE-AF Investigators

Journal: New England Journal of Medicine

Citation: Kim D, Lee YS, Shim J, et al. Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk. N Engl J Med. Published August 28, 2026. DOI: 10.1056/NEJMoa2607978

Link: https://doi.org/10.1056/nejmoa2607978


Clinical Question

Should patients with atrial fibrillation at intermediate stroke risk (CHA2DS2-VASc 1 in men, 2 in women) receive oral anticoagulation?

Bottom Line

In patients with atrial fibrillation at intermediate stroke risk, DOAC therapy reduced the composite of stroke, systemic embolism, major bleeding, or cardiovascular death at 24 months compared with no anticoagulation (0.5% vs 1.5%; HR 0.31), without an apparent increase in major bleeding — providing randomized-trial support for anticoagulating this class IIa population.

Major Points

  • First randomized trial directly comparing DOAC therapy with no anticoagulation in intermediate-stroke-risk atrial fibrillation (CHA2DS2-VASc 1 in men, 2 in women).
  • Primary composite end point (stroke, systemic embolism, major bleeding, or cardiovascular death) at 24 months: 0.5% with DOAC vs 1.5% with no anticoagulation (difference −1.0 pp; 95% CI −2.0 to −0.1; P=0.03; HR 0.31; 95% CI 0.10–0.94).
  • Stroke: 0.3% vs 1.1% (HR 0.30; 95% CI 0.08–1.08); post hoc ischemic stroke or systemic embolism: 0.1% vs 1.1% (HR 0.10; 95% CI 0.01–0.77).
  • Major bleeding was similar between groups (0.3% vs 0.5%; HR 0.75); no cardiovascular deaths occurred in either group.
  • Win-ratio sensitivity analysis favored DOAC (3.31; 95% CI 1.15–9.54); treatment effect appeared consistent across subgroups.
  • Event rates were far lower than the assumptions used for the power calculation (0.5%/1.5% observed vs 2.0%/4.5% assumed).
  • Apixaban 5 mg was the most commonly used DOAC (67.4%); DOACs were full-dose in 81.6% of treated patients; 36.5% of the no-anticoagulant group received antiplatelet therapy.

Design

Study Type: Investigator-initiated, multicenter, open-label, randomized superiority trial with blinded (adjudicator-masked) outcome adjudication

Randomization: 1

Blinding: Open-label with blinded adjudication of outcome events by an independent clinical-events committee

Allocation: 1:1, Web-based system, permuted-block design (block sizes 4 or 6), stratified by trial site

Enrollment Period: July 27, 2020 through June 29, 2023

Follow-up Duration: 24 months (median follow-up 730 days); assessments at baseline and 3, 6, 12, 18, and 24 months

Centers: 18

Countries: South Korea

Sample Size: 1803

Analyzed: 1803

Analysis: Intention-to-treat; cumulative incidence by Aalen–Johansen method with noncardiovascular death as competing event; treatment effects by Fine–Gray subdistribution hazard models; no multiplicity correction for secondary/subgroup analyses

Power Calculation: Assuming 24-month primary event incidence of 2.0% (DOAC) vs 4.5% (no anticoagulation), 1800 patients (900 per group) provided 80% power to detect a 2.5-percentage-point difference at two-sided alpha 0.05, with assumed 12% attrition

Registration: ClinicalTrials.gov NCT04437654


Inclusion Criteria

  • Age ≥19 years
  • Atrial fibrillation
  • Intermediate risk of stroke (CHA2DS2-VASc score of 1 in men or 2 in women)

Exclusion Criteria

  • Clinically significant kidney disease (serum creatinine ≥3.5 mg/dL or creatinine clearance <30 mL/min)
  • Clinically significant liver disease (AST or ALT >3x upper limit of normal, or Child–Pugh class B or C)
  • Use of anticoagulation for mechanical prosthetic valve, moderate-to-severe mitral stenosis, or deep-vein thrombosis
  • Clinically significant structural heart disease (e.g., dilated or hypertrophic cardiomyopathy, cardiac amyloidosis)

Baseline Characteristics

CharacteristicDOAC Therapy (N=902)No Anticoagulant Therapy (N=901)
Mean age (yr)60.7±7.860.0±8.1
Age ≥65 yr304 (33.7%)282 (31.3%)
Male sex682 (75.6%)694 (77.0%)
Paroxysmal AF636 (70.5%)658 (73.0%)
Nonparoxysmal AF266 (29.5%)243 (27.0%)
Median time since AF diagnosis (mo)21 (IQR 2–60)21 (IQR 2–58)
Hypertension435 (48.2%)482 (53.5%)
Diabetes mellitus67 (7.4%)70 (7.8%)
Heart failure93 (10.3%)72 (8.0%)
Stroke or TIA0 (0%)2 (0.2%)
Dyslipidemia224 (24.8%)193 (21.4%)
Myocardial infarction3 (0.3%)2 (0.2%)

Arms

FieldDOAC TherapyControl
N902901
InterventionApixaban 5 mg twice daily (67.4%) or rivaroxaban 20 mg once daily, at physician's discretion, with prespecified dose reductions (full dose in 81.6%, reduced dose in 18.4%); alternative DOAC permitted for unacceptable side effectsNo routine oral anticoagulation; temporary DOAC permitted around rhythm-control interventions (cardioversion/catheter ablation); antiplatelet therapy permitted if clinically indicated (used in 36.5%)
Duration24 months24 months

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Composite of stroke, systemic embolism, major bleeding (ISTH-defined), or death from cardiovascular causes (amended January 2025 from death from any cause, before unblinding, by the DSMB)Primary13/901 (cumulative incidence 1.5%)4/902 (cumulative incidence 0.5%)0.31P=0.03
Stroke at 24 monthsSecondary10 patients (1.1%)3 patients (0.3%)HR 0.30 (95% CI 0.08–1.08)
Systemic embolism at 24 monthsSecondary1 patient (0.1%)0 patients
Death from any cause at 24 monthsSecondary5 patients (0.6%)3 patients (0.3%)HR 0.60 (95% CI 0.14–2.51)
Death from cardiovascular causesSecondary0 patients0 patientsNo events in either group
Transient ischemic attack at 24 monthsSecondary3 patients (0.3%)0 patients
Ischemic stroke or systemic embolism at 24 months (post hoc)Secondary10 patients (1.1%)1 patient (0.1%)HR 0.10 (95% CI 0.01–0.77)
Win ratio (sensitivity analysis, hierarchical: CV death, intracranial hemorrhage, ischemic stroke/systemic embolism, major bleeding excluding ICH)SecondaryWin ratio 3.31 (95% CI 1.15–9.54) favoring DOAC
Major bleeding (ISTH) at 24 monthsSafety4 patients (0.5%)3 patients (0.3%)HR 0.75 (95% CI 0.17–3.35)
Clinically relevant nonmajor bleeding at 24 monthsSafety14 patients (1.6%)22 patients (2.5%)HR 1.58 (95% CI 0.81–3.08)
Serious adverse events - DOACAdverse80 patients (8.9%)
Serious adverse events - No anticoagulationAdverse84 patients (9.3%)

Subgroup Analysis

The effect of DOAC therapy on the primary end point appeared consistent across prespecified subgroups; a post hoc subgroup analysis by AF type (paroxysmal vs nonparoxysmal) was also performed. A sensitivity analysis censoring follow-up when the CHA2DS2-VASc score rose to a class I anticoagulation indication (≥2 in men, ≥3 in women; occurred in 16.7% of DOAC and 13.3% of no-anticoagulant patients) was consistent with the primary analysis.


Criticisms

  • Open-label design (though outcome adjudication was blinded)
  • Conducted entirely in South Korea with a predominantly male (76%) population, limiting generalizability
  • Observed event rates (0.5% vs 1.5%) were much lower than the assumed 2.0% vs 4.5%, yielding few events (4 vs 13) and wide confidence intervals
  • Primary end point was amended during the trial (death from any cause narrowed to cardiovascular death), although this was done by the blinded DSMB and described previously
  • 36.5% of the no-anticoagulant group received antiplatelet therapy and 5.5% crossed over to DOAC, which could attenuate or confound the comparison
  • No multiplicity adjustment for secondary and subgroup analyses

Funding

Ministry of Health and Welfare, South Korea; Samjin Pharmaceutical; Hanmi Pharmaceutical. Funders had no role in trial design, conduct, analysis, or manuscript preparation.

Based on: SINGLE-AF (New England Journal of Medicine, 2026)

Authors: Daehoon Kim, Young Soo Lee, Jaemin Shim, ..., for the SINGLE-AF Investigators

Citation: Kim D, Lee YS, Shim J, et al. Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk. N Engl J Med. Published August 28, 2026. DOI: 10.1056/NEJMoa2607978

Content summarized and formatted by NeuroTrials.ai.